Value-based pricing of a COVID-19 vaccine

This article has been Reviewed by the following groups

Read the full article

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2021.03.06.21253035: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.


    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    As a word of caution, given the time constraints and the rapid inflow of new information on the SARS-CoV-2 pandemic while conducting the study and writing this manuscript, which made it necessary to update the projections continuously, this decision-analytic study has several caveats. There are reasons why the study underestimates the health benefits and cost-effectiveness of a vaccine compared to the alternative strategies, and its value-based price. Some of these reasons were already captured in the sensitivity analysis and include a high probability of ICU admission. First, the study does not consider the deaths and loss of health-related quality of life associated with the shutdown and social distancing, e.g., due to depressive or anxiety disorders, suicides, unemployment, domestic violence, and fewer emergency and regular visits to physicians for unrelated medical conditions. Nevertheless, as mentioned in the Methods section, official data on excess mortality in Germany (Federal Office of Statistics 2020) show that the peak in excess mortality in the first half of April and the rising mortality in November both coincided with the surges in COVID-19 deaths, thus indicating that excess mortality was driven by COVID-19 and not by other causes. Second, unaffected individuals may experience a loss of personal freedom (Abele-Brehm 2020) and autonomy under lockdown. Third, under mitigation strategy elective procedures may need to be deferred if ICU capacity is expected to be in...

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.